Intellia Broadens Its Oncology Bets With CRISPR-Edited NK Cell Therapies
Partners ONK Therapeutics To Develop Five Candidates
Intellia continues to expand across immuno-oncology, adding the promise of natural killer cells to its pipeline.
You may also be interested in...
AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.
The first use of CRISPR/Cas9 in humans shows promising safety and efficacy against rare disease ATTR, and opens up the possibility of treating many genetic diseases.
Blackstone is providing $250m to combine Intellia’s gene editing and Cellex’s cell manufacturing capabilities in a new CAR-T company using Cellex subsidiary GEMoaB’s technology and pipeline as a foundation.